Use of NSAIDs via the Rectal Route for the Prevention of Pancreatitis after ERCP in All-Risk Patients: An Updated Meta-Analysis

Table 2

Outcome data of studies included in the meta-analysis.

Study	Comparison	Number of patients	Severity of post-ERCP pancreatitis			Serum amylase (IU/L) 2 h after ERCP (mean ± SD)	Serum amylase (IU/L) 4 h after ERCP (mean ± SD)
			Incidence of post-ERCP pancreatitis	Mild	Moderate to severe
Andrade-Dávila et al. [15]	Indomethacin	82	4/82	3	1	141.90 ± 92.60	NA
	Placebo	84	17/84	14	3	216.50 ± 105.20	NA
Döbrönte et al. [6]	Indomethacin	347	20/347	16	4	NA	NA
	Placebo	318	22/318	18	4	NA	NA
Elmunzer et al. [10]	Indomethacin	295	27/295	14	13	NA	NA
	Placebo	307	52/307	25	27	NA	NA
Khoshbaten et al. [11]	Diclofenac	50	2/50	NA	NA	310.28 ± 320.61	342.22 ± 331.65
	Placebo	50	13/50	NA	NA	667.80 ± 1034.15	948.86 ± 1296.69
Levenick et al. [8]	Indomethacin	223	16/223	16	0	NA	NA
	Placebo	226	11/226	9	2	NA	NA
Montaño et al. [16]	Indomethacin	75	4/75	4	0	148.22 ± 190.60	NA
	Placebo	75	12/75	12	0	240.73 ± 256.20	NA
Murray et al. [12]	Diclofenac	110	7/110	7	0	313.00 ± 398.54	321.00 ± 597.82
	Placebo	110	17/110	15	2	400.00 ± 702.70	507.00 ± 943.92
Otsuka et al. [13]	Diclofenac	51	2/51	2	0	NA	NA
	Placebo	53	10/53	7	3	NA	NA
Patai et al. [17]	Indomethacin	270	18/270	15	3	NA	NA
	Placebo	269	37/269	33	4	NA	NA
Shafique et al. [14]	Diclofenac	54	9/54	NA	NA	NA	NA
	Placebo	54	22/54	NA	NA	NA	NA
Sotoudehmanesh et al. [18]	Indomethacin	221	7/221	7	0	472.70 ± 910.40	NA
	Placebo	221	15/221	10	5	494.30 ± 694.10	NA

NSAIDs: nonsteroidal anti-inflammatory drugs; ERCP: endoscopic retrograde cholangiopancreatography; SD: standard deviation; NA: not available.